Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project.
Saved in:
| Title: | Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. |
|---|---|
| Authors: | Foster M; Science Applications International Corporation (SAIC), Reston, VA 20190, USA., Negash Y; Science Applications International Corporation (SAIC), Reston, VA 20190, USA., Eberhardt L; Science Applications International Corporation (SAIC), Reston, VA 20190, USA., Bryan WW; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Schultz K; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Wang X; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Xu Y; Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., George B; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. |
| Source: | Molecular therapy oncolytics [Mol Ther Oncolytics] 2022 Oct 20; Vol. 27, pp. 182-194. Date of Electronic Publication: 2022 Oct 20 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36381656 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Foster+M%22">Foster M</searchLink>; Science Applications International Corporation (SAIC), Reston, VA 20190, USA.<br /><searchLink fieldCode="AU" term="%22Negash+Y%22">Negash Y</searchLink>; Science Applications International Corporation (SAIC), Reston, VA 20190, USA.<br /><searchLink fieldCode="AU" term="%22Eberhardt+L%22">Eberhardt L</searchLink>; Science Applications International Corporation (SAIC), Reston, VA 20190, USA.<br /><searchLink fieldCode="AU" term="%22Bryan+WW%22">Bryan WW</searchLink>; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.<br /><searchLink fieldCode="AU" term="%22Schultz+K%22">Schultz K</searchLink>; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.<br /><searchLink fieldCode="AU" term="%22Xu+Y%22">Xu Y</searchLink>; Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.<br /><searchLink fieldCode="AU" term="%22George+B%22">George B</searchLink>; Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101666776%22">Molecular therapy oncolytics</searchLink> [Mol Ther Oncolytics] 2022 Oct 20; Vol. 27, pp. 182-194. <i>Date of Electronic Publication: </i>2022 Oct 20 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101666776 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2372-7705 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223727705%22">23727705 </searchLink><i>NLM ISO Abbreviation: </i>Mol Ther Oncolytics <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36381656 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.omto.2022.10.006 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 182 Titles: – TitleFull: Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Foster M – PersonEntity: Name: NameFull: Negash Y – PersonEntity: Name: NameFull: Eberhardt L – PersonEntity: Name: NameFull: Bryan WW – PersonEntity: Name: NameFull: Schultz K – PersonEntity: Name: NameFull: Wang X – PersonEntity: Name: NameFull: Xu Y – PersonEntity: Name: NameFull: George B IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 10 Text: 2022 Oct 20 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 2372-7705 Numbering: – Type: volume Value: 27 Titles: – TitleFull: Molecular therapy oncolytics Type: main |
| ResultId | 1 |
